“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A study looking at 2 types of scan to see how well a type of biological therapy works to treat kidney cancer
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is looking at 2 types of scans. The researchers want to see how well a PET-CT scan and CT scan show up changes to kidney cancer being treated with a type of biological therapy called a tyrosine kinase inhibitor.
At the moment, the only way doctors can measure how well the drug is working is by taking samples of the cancer (biopsies) and looking at them under a microscope.
In this study, they are looking to see if these new scans can show how well the drug is working. If scan results are promising, they may be used in future to help doctors decide which patients are most likely to benefit from taking this type of drug.
Who can enter
You may be able to enter this study if
- You have a type of kidney cancer called renal cell cancer
- Your cancer has either grown into surrounding tissues or spread to another part of your body
- Your doctor thinks that treatment with a type of drug called a tyrosine kinase inhibitor will help you
- Doctors could easily measure your cancer on a scan
- Your kidneys are working well enough to get rid of the study drug
- You would be able to cope with the scans
- You are at least 18 years old
You cannot enter this study if you
- Have had any cancer treatment in the last month
- Are allergic to the scan injection or any of its ingredients – you can ask your doctor about this
- Are pregnant or breastfeeding
- Have any other condition that would make you unwell if you took part, or affect the results of the study – you can ask your doctor about this
This study will recruit between 40 and 50 people. Everyone taking part will be due to start having a tyrosine kinase inhibitor. This treatment would have already been planned. For the study, you will have 2 types of scan, called an F-RGD PET-CT scan and a perfusion CT scan. You have the scans
- Before you start your course of treatment
- 4 weeks after starting this treatment
- 16 weeks after starting treatment
You have both scans at each appointment. When you come for your scans each time, the team will put a small thin plastic tube into a vein in your arm. You then have an injection of a radioactive tracer through this tube. This helps show up the cancer’s blood supply on the scan. You then have the F-RGD PET-CT scan, which will take about an hour. For the first 20 minutes of this you will need to lie very still on your back.
After this you have a perfusion CT scan. The team will inject a special dye into your veins to show things up more clearly on this scan. The CT scan takes about a minute.
Before you go home you see the doctor and have a physical examination. You should be able to go home an hour after the radioactive tracer injection.
Before you join the study you will see the doctor. You may need to have a blood test if this has not already been done.
You may also need to have other tests. The team will tell you more about this if it affects you. Where possible, you have this first visit when you are already at the hospital for your first study scan.
You make 3 hospital visits for your study scans. Each scan visit will last about 2 hours.
Side effects of the PET-CT scan injection include
- Small risk of bleeding and risk of infection where you had the injection
- Allergic reaction, which could be very severe – this is very rare and staff will monitor and treat you for this if needed
You will be exposed to a small amount of radioactivity from the PET-CT scan tracer injections. The radiation from these injections fades over time and most of it will have gone after 6 hours. So after these scans you need to stay at least 2 metres away from children and pregnant women, for at least 6 hours.
You will also be exposed to a little extra radiation from the study scans themselves. Being exposed to radiation can increase your risk of developing cancer. The team believe that the risk of developing a second cancer from these scans is small.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Fergus Gleeson
Experimental Cancer Medicine Centre (ECMC)
Oxford University Hospitals NHS Trust